Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMK4VY9)

• Drug Name: DS-7300 Drug Info
• Synonyms: O-(3,5-dichlorophenyl)hydroxylamine; 99907-90-1; 3,5-Dichlorophenoxyamine; Hydroxylamine, O-(3,5-dichlorophenyl)-; SCHEMBL4210449; DTXSID00471352; MFCD09029771; ZINC21987339; AKOS006290319; AK141702

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[1]

• Cross-matching ID:
  PubChem CID: 11736040
  TTD Drug ID: DMK4VY9

Molecule-Related Drug Atlas

Drug(s) Targeting DNA topoisomerase I (TOP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[3]
Topotecan	DMP6G8T	Central nervous system neoplasm		Approved	[3]
B-Lactams	DMR8YD6	Bacterial infection	1A00-1C4Z	Approved	[4]
Belotecan hydrocholoride	DM3SRJZ	Small-cell lung cancer	2C25.Y	Approved	[5]
Topetecan	DMAE6LK	Small-cell lung cancer	2C25.Y	Approved	[6]
Karenitecin	DMCRGY4	Lung cancer	2C25.0	Phase 3	[7]
Camptothecin	DM6CHNJ	Solid tumour/cancer	2A00-2F9Z	Phase 3	[8]
Exatecan	DMCA7FN	Solid tumour/cancer	2A00-2F9Z	Phase 3	[9]
Edotecarin	DM3ZL7D	Gastric adenocarcinoma	2B72	Phase 3	[10]
Rubitecan	DMDWU1S	Human immunodeficiency virus infection	1C62	Phase 3	[11]

Drug(s) Targeting B7 homolog 3 (CD276)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Omburtamab I-131	DMPDA17	Neuroblastoma	2D11.2	Phase 2/3	[12]
131 I-omburtamab	DM12UX6	Brain and central nervous system tumour	2A00.11	Phase 2/3	[13]
Omburtamab	DMTIESG	Neuroblastoma	2D11.2	Phase 2/3	[14]
Enoblituzumab	DMDS20X	Prostate cancer	2C82.0	Phase 2	[15]
TAK-280	DM08RE5	Aggressive cancer	2A00-2F9Z	Phase 2	[16]
Omburtamab I-124	DMPLBDF	Glioma	2A00.0	Phase 1/2	[12]
MGC018	DM1KZW0	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[17]
MGD009	DME4B8I	Solid tumour/cancer	2A00-2F9Z	Phase 1	[15]
MGA271	DM2PVLH	Metastatic cancer	2D50-2E2Z	Phase 1	[18]
124I-8H9	DM5ZC0E	Glioblastoma multiforme	2A00.0	Phase 1	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B7 homolog 3 (CD276)	TT6CQUM	CD276_HUMAN	Inhibitor	[2]
DNA topoisomerase I (TOP1)	TTGTQHC	TOP1_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT04145622) Study of DS-7300a in Participants With Advanced Solid Malignant Tumors. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Daiichi Sankyo.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [4] Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I. Biochem J. 2002 Sep 1;366(Pt 2):653-61.
• [5] Impact of natural products on developing new anti-cancer agents. Chem Rev. 2009 Jul;109(7):3012-43.
• [6] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [7] Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350. Mol Pharmacol.2000 Mar;57(3):453-9.
• [8] Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006 Oct;6(10):789-802.
• [9] Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks. Clin Cancer Res. 2001 Dec;7(12):3963-70.
• [10] Edotecarin: a novel topoisomerase I inhibitor. Clin Colorectal Cancer. 2005 May;5(1):27-36.
• [11] Rubitecan. Expert Opin Investig Drugs. 2006 Jan;15(1):71-9.
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] IntraOmmaya compartmental radioimmunotherapy using 131 I-omburtamab-pharmacokinetic modeling to optimize therapeutic index. Eur J Nucl Med Mol Imaging. 2021 Apr;48(4):1166-1177.
• [14] Mast cell proliferation in the cerebrospinal fluid after intraventricular administration of anti-B7H3 immunotherapy. Cancer Immunol Immunother. 2021 Feb 3.
• [15] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [16] ClinicalTrials.gov (NCT05220098) A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer. U.S.National Institutes of Health.
• [17] Clinical pipeline report, company report or official report of MacroGenics.
• [18] T Cell Coinhibition and Immunotherapy in Human Breast Cancer. Discov Med. 2012 October; 14(77): 229-236.
• [19] National Cancer Institute Drug Dictionary (drug id 722029).